About Ricardo Baptista

Under the auspices of UNAIDS, Ricardo is the Founder and President of ‘UNITE – Parliamentarians Network to End HIV/AIDS, Viral Hepatitis and Tuberculosis’, a global platform of policy makers.

Awarded by ‘The Economist Intelligence Unit’ as a ‘HCV Change Maker’ (2016). This acknowledgment, attributed to solely six people globally, came in due recognition of Ricardo’s academic work and policy leadership in the field of hepatitis c.

Member of the Portuguese Parliament, currently on a 2nd term (2011-Present), serving as a permanent member of the Parliamentary Health Committee and of the Parliamentary Foreign Affairs Committee and having served as Vice-President of the Foreign Affairs Committee, permanent member of the Parliamentary group on Population and Development, Chair of the all-party Parliamentary HIV/AIDS workgroup and President of the Portuguese-Canadian Parliamentary Friendship Group.

Head of Public Health at the Institute of Health Sciences of Católica University of Portugal. Guest Lecturer at NOVA Medical School (Infectious Diseases and Microbiology) and at NOVA Information Management School (Coordinator of Sustainable Healthcare Unit), both at NOVA University. Senior Fellow at New Westminster College (BC, Canada) and PhD candidate in Public Health and Health Systems at Maastricht University (The Netherlands). Elected member of the supervisory board of the National Genetic Database Protection Agency. A decade of experience in health technology as a medical consultant at Glintt Healthcare Solutions (2009-2016), a multinational software house.

From 2015 to 2017, Deputy Mayor and City Councilor of Cascais, responsible for local health policy, academic partnerships, international relations (including economic diplomacy), youth (including Cascais European Youth Capital 2018) and employment policies.

In the past, practicing physician during 7 years, including a 5-year Infectious Diseases residency program at the Western Lisbon Hospital Center. Intern in public health (HIV, Hepatitis and STI’s) as a formal collaborator of the World Health Organization Regional Office for Europe, based in Copenhagen (2011). 

This speaker will be presenting at the following session(s)

  • Policy as a tool for HepC Elimination

    Matisse

    Day: 1 November

    Time: 17:30

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe.

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe. Hepatitis C is a chronic infectious disease with great impact on patients’ morbidity and mortality, with high risk of progression to cirrhosis and liver cancer. In Europe, it is estimated that only 25% of patients with hepatitis C are diagnosed (~14 million people); each year there are 27,000-29,000 newly diagnosed HCV cases in the EU/EEA. Evidence shows that, for some European countries, annual deaths from hepatitis c have quadrupled over the past 20 years. New treatments were recently discovered that cures hepatitis C in up to 97% of cases. This, alongside the devastating effects that the disease can have, means that the paradigm at the community level of hepatitis c treatment should now be elimination.

    Presentations:

    • From policy to action.
      Charles Gore, World Hepatitis Alliance
    • What matters to patients - HepCore.
      Prof. Jeffrey Lazarus, University of Copenhagen
    • Empowering advocates.
      Achim Kautz, Leberhilfe Projekt gUG
    • Modelling for policy change.
      Dr. Homie A. Razavi, Center for Disease Analysis Foundation
    • Brazil strategy and response to HCV.
      Evaldo Stanislau Affonso de Araújo, Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo
    • Let's End HepC Dashboard - assessing and comparing different Countries policies in real-time towards the elimination of HCV until 2030.
      Ricardo Baptista Leite, Member of the Portuguese Parliament and Católica University of Portugal